Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21361616 | 0.91 | ALDH1A1 (0.41) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL21361542 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL25435310 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP19A1ALDH1A1POLBTSHR | |
| SCHEMBL21361419 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP19A1ALDH1A1POLBTSHR | |
| SCHEMBL21361573 | 0.86 | ALDH1A1 (0.38) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL21361571 | 0.86 | ALDH1A1 (0.38) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL21361537 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL23102217 | 0.83 | CYP19A1 (0.43) | SMN1; SMN2CYP19A1POLBNPSR1 | |
| SCHEMBL21361487 | 0.83 | LMNA (0.43) | SMN1; SMN2CYP19A1ALDH1A1POLBCYP3A4 | |
| SCHEMBL21361409 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2CYP3A4CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | SMN1; SMN2 4582/4885CYP19A1 1524/4885ALDH1A1 4848/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | SMN1; SMN2 4499/4885CYP19A1 1509/4885ALDH1A1 4834/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | SMN1; SMN2 4421/4885CYP19A1 1448/4885ALDH1A1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.